NASDAQ:AQB - Aquabounty Technologies Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aquabounty Technologies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.65 -0.11 (-6.25 %) (As of 02/18/2020 09:03 AM ET) Add Compare Today's Range$1.65Now: $1.65▼$1.8750-Day Range$1.52MA: $2.15▼$2.6652-Week Range$1.52Now: $1.65▼$5.45Volume129,375 shsAverage Volume206,538 shsMarket Capitalization$35.64 millionP/E RatioN/ADividend YieldN/ABeta1.03 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email AquaBounty Technologies, Inc, a biotechnology company, develops and markets products to enhance productivity in aquaculture. It offers AquAdvantage Salmon, a genetically modified Atlantic salmon for human consumption. The company was formerly known as Aqua Bounty Farms, Inc and changed its name to AquaBounty Technologies, Inc in June 2004. AquaBounty Technologies, Inc was founded in 1991 and is headquartered in Maynard, Massachusetts. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Fishing, hunting & trapping Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AQB Previous Symbol CUSIPN/A CIK1603978 Webhttp://www.aquabounty.com/ Phone978-648-6000Debt Debt-to-Equity Ratio0.18 Current Ratio5.61 Quick Ratio5.25Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$90,000.00 Price / Sales396.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.54 per share Price / Book1.07Profitability EPS (Most Recent Fiscal Year)($0.94) Net Income$-10,380,000.00 Net Margins-7,510.69% Return on Equity-45.56% Return on Assets-37.51%Miscellaneous Employees39 Outstanding Shares21,600,000Market Cap$35.64 million Next Earnings Date3/5/2020 (Estimated) OptionableNot Optionable Receive AQB News and Ratings via Email Sign-up to receive the latest news and ratings for AQB and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:AQB Rates by TradingView Aquabounty Technologies (NASDAQ:AQB) Frequently Asked Questions What is Aquabounty Technologies' stock symbol? Aquabounty Technologies trades on the NASDAQ under the ticker symbol "AQB." How were Aquabounty Technologies' earnings last quarter? Aquabounty Technologies Inc (NASDAQ:AQB) released its quarterly earnings results on Tuesday, November, 5th. The company reported ($0.14) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.17) by $0.03. Aquabounty Technologies had a negative net margin of 7,510.69% and a negative return on equity of 45.56%. View Aquabounty Technologies' Earnings History. When is Aquabounty Technologies' next earnings date? Aquabounty Technologies is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Aquabounty Technologies. What price target have analysts set for AQB? 2 brokerages have issued 12-month price objectives for Aquabounty Technologies' stock. Their forecasts range from $4.00 to $5.00. On average, they expect Aquabounty Technologies' stock price to reach $4.50 in the next twelve months. This suggests a possible upside of 172.7% from the stock's current price. View Analyst Price Targets for Aquabounty Technologies. What is the consensus analysts' recommendation for Aquabounty Technologies? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aquabounty Technologies in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aquabounty Technologies. What are Wall Street analysts saying about Aquabounty Technologies stock? Here are some recent quotes from research analysts about Aquabounty Technologies stock: 1. According to Zacks Investment Research, "AquaBounty Technologies, Inc. is a biotechnology company. It focused on enhancing productivity in aquaculture. The company operates primarily in Maynard, Massachusetts and Fortune, Prince Edward Island. AquaBounty Technologies, Inc. is based in Maynard, United States. " (1/14/2020) 2. National Securities analysts commented, " Second Quarter Results. An operating loss of $4.0 million fell below our estimated loss of $2.8 million, driven largely by sequential increases in G&A from $2.0 million in the first quarter to $3.1 million in the second quarter. We believe some of the increases were one time in nature, although we believe our prior OpEx estimates in advance of commercialization were too light. Production Schedule On Track. With AquAdvantage Salmon (AAS) in the Indiana and Rollo Bay grow out facilities, we continue to expect initial harvests by the end of 2020. A one-time harvest of conventional salmon is also expected in the third quarter of 2020. We look for a regular introduction of AAS into the grow out phase which should enable year-round harvest. What Is Next? With production now underway in both facilities, we believe management is focused on securing buyers for the initial harvest and making preliminary estimates on future expansion. The commercial team is being developed, highlighted by the introduction of CCO David Melbourne Jr in the quarter. We believe expansion plans will be formally announced as commercial revenues are realized and will initially be an expansion of the current Indiana facility. Initial AAS Buyer The Next Major Catalyst. We believe a formal announcement of the first buyers of AAS will represent a significant catalyst for the stock. With the first harvest of AAS anticipated in the third quarter of 2020, we expect buyers to commit around the Spring of 2020. We expect investors on the sideline are awaiting this announcement, and thus believe as buyers are secured and visibility of revenue is enhanced that shares will make a meaningful and sustainable movement upward." (8/7/2019) Has Aquabounty Technologies been receiving favorable news coverage? News stories about AQB stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aquabounty Technologies earned a daily sentiment score of 1.1 on InfoTrie's scale. They also gave media stories about the company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an effect on the company's share price in the immediate future. View News Stories for Aquabounty Technologies. Are investors shorting Aquabounty Technologies? Aquabounty Technologies saw a decline in short interest in January. As of January 31st, there was short interest totalling 274,200 shares, a decline of 11.2% from the January 15th total of 308,900 shares. Based on an average daily trading volume, of 70,300 shares, the short-interest ratio is presently 3.9 days. Approximately 2.4% of the company's shares are sold short. View Aquabounty Technologies' Current Options Chain. Who are some of Aquabounty Technologies' key competitors? Some companies that are related to Aquabounty Technologies include Liquidia Technologies (LQDA), 22nd Century Group (XXII), IDEAYA Biosciences (IDYA), PhaseBio Pharmaceuticals (PHAS), MediGene (MDG1), Green Organic Dutchman (TGODF), Aravive (ARAV), 1300 Smiles (ONT), Newron Pharmaceuticals (NWPHF), Immutep (IMM), Monopar Therapeutics (MNPR), Fonar (FONR), OncoCyte (OCX), OncoCyte (OCX) and BRAINSWAY LTD/S (BWAY). What other stocks do shareholders of Aquabounty Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aquabounty Technologies investors own include Celldex Therapeutics (CLDX), Intrexon (XON), Aurora Cannabis (ACB), Ocular Therapeutix (OCUL), NovaBay Pharmaceuticals (NBY), Adaptimmune Therapeutics (ADAP), Genocea Biosciences (GNCA), Rigel Pharmaceuticals (RIGL), Rockwell Medical (RMTI) and Viking Therapeutics (VKTX). Who are Aquabounty Technologies' key executives? Aquabounty Technologies' management team includes the folowing people: Mr. David A. Frank, CFO & Treasurer (Age 59)Dr. Ronald L. Stotish, Exec. Director & Chief Technology Officer (Age 70)Mr. Alejandro Rojas, Chief Operating Officer of Aquabounty Farms (Age 57)Ms. Sylvia Wulf, CEO, Pres & Exec. Director (Age 61)Mr. Christopher H. Martin, Gen. Counsel & Company Sec. (Age 53) Who are Aquabounty Technologies' major shareholders? Aquabounty Technologies' stock is owned by many different of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (1.88%), KBC Group NV (0.29%), Ladenburg Thalmann Financial Services Inc. (0.28%), Renaissance Technologies LLC (0.27%) and Winthrop Advisory Group LLC (0.09%). View Institutional Ownership Trends for Aquabounty Technologies. Which major investors are selling Aquabounty Technologies stock? AQB stock was sold by a variety of institutional investors in the last quarter, including Ladenburg Thalmann Financial Services Inc.. View Insider Buying and Selling for Aquabounty Technologies. Which major investors are buying Aquabounty Technologies stock? AQB stock was purchased by a variety of institutional investors in the last quarter, including KBC Group NV, Renaissance Technologies LLC, ARK Investment Management LLC and Winthrop Advisory Group LLC. View Insider Buying and Selling for Aquabounty Technologies. How do I buy shares of Aquabounty Technologies? Shares of AQB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Aquabounty Technologies' stock price today? One share of AQB stock can currently be purchased for approximately $1.65. How big of a company is Aquabounty Technologies? Aquabounty Technologies has a market capitalization of $35.64 million and generates $90,000.00 in revenue each year. The company earns $-10,380,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis. Aquabounty Technologies employs 39 workers across the globe.View Additional Information About Aquabounty Technologies. What is Aquabounty Technologies' official website? The official website for Aquabounty Technologies is http://www.aquabounty.com/. How can I contact Aquabounty Technologies? Aquabounty Technologies' mailing address is 2 MILL & MAIN PLACE SUITE 395, MAYNARD MA, 01754. The company can be reached via phone at 978-648-6000 or via email at [email protected] MarketBeat Community Rating for Aquabounty Technologies (NASDAQ AQB)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 160 (Vote Outperform)Underperform Votes: 176 (Vote Underperform)Total Votes: 336MarketBeat's community ratings are surveys of what our community members think about Aquabounty Technologies and other stocks. Vote "Outperform" if you believe AQB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AQB will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/18/2020 by MarketBeat.com StaffFeatured Article: What is the Euro STOXX 50 Index?
